FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387208071> ?p ?o ?g. }

• W4387208071 endingPage "S41" @default.
• W4387208071 startingPage "S41" @default.
• W4387208071 abstract "Hypofractionation for definitive concurrent chemoradiation (CCRT) in locally advanced cervical cancer (LACC) may increase RT efficacy but scarce in data. Early results of HYPOCx-iRex trial at 3-mo follow-up (F/U) time showed a non-statistically significant small rise but auto-resolved acute GI toxicity of HYPO 44 Gy/20F arm compared to CVRT 45 Gy/25F arm, yet significantly retracted overall treatment time and time to brachytherapy without compromised GTV reduction or tumor response. This prespecified interim analysis at 6-mo post-RT of the first 20 patients was intended to prove non-inferior late toxicity, oncologic outcome and pattern of failure of HYPO in addition to previous ESTRO2023 abstract.Patients with LACC were enrolled since July 2021. ≥3 Pelvic LN or at/above common iliac were excluded to omit paraaortic RT. Open-label randomization was performed for IMRT/VMAT to HYPO for 44 Gy/20F to whole pelvis and 53 Gy/20F SIB to gross LN in five-day-a-week fractions, and for CVRT 45 and 55 Gy/25F, with concurrent weekly cisplatin 40 mg/m2. Target contour and planning dose of EBRT and IGABT were adapted and biologically converted from EMBRACE-II. Indirect ratio of excess dose volume (iRex; DOI: 10.5114/jcb.2020.100377) as a complimentary low-dose conformity index to D2cc-based IGABT was explored, but analysis was out of this abstract scope. Non-inferiority margin of 9% 5-yr GI toxicity difference of HYPO and CVRT with one-sided α = 0.5 and 1-β = 0.8 yielded 40-patient sample size for toxicity screening. Adopting 9% margin, analysis at 6-mo post-RT of the first 20 patients were done with descriptive and survival analysis.Twenty-nine patients with median F/U time from start of RT of 8 months were included. Non-significant difference of IGABT dose was seen. Median post-RT time were 7 months with non-significant difference in 6-mo crude, late and persistent (LAPER), or cumulative GI and GU toxicity. Unfortunately, difference of -0.07 [95% CI -0.47 to +0.32] cumulative GI toxicity exceeded margin of +0.09, but the p value is greater than 0.5 (cut-off for go or no go for phase III study). No significant oncologic outcome nor pattern of failure difference were shown.HYPO 44 Gy/20F showed trend of non-significant difference in 6-mo toxicity nor oncologic outcome. The unmet non-inferior margin should be re-evaluated at trial completion for further implementation." @default.
• W4387208071 created "2023-09-30" @default.
• W4387208071 creator A5007722215 @default.
• W4387208071 creator A5025004941 @default.
• W4387208071 creator A5039000174 @default.
• W4387208071 creator A5042095217 @default.
• W4387208071 date "2023-10-01" @default.
• W4387208071 modified "2023-10-17" @default.
• W4387208071 title "HYPOCx-iRex (TCTR20210812003) A Phase II RCT: 44 Gy/20F VS 45 Gy/25F CCRT in Cervical Cancer: Six-month Post-RT Update" @default.
• W4387208071 doi "https://doi.org/10.1016/j.ijrobp.2023.06.313" @default.
• W4387208071 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784494" @default.
• W4387208071 hasPublicationYear "2023" @default.
• W4387208071 type Work @default.
• W4387208071 citedByCount "0" @default.
• W4387208071 crossrefType "journal-article" @default.
• W4387208071 hasAuthorship W4387208071A5007722215 @default.
• W4387208071 hasAuthorship W4387208071A5025004941 @default.
• W4387208071 hasAuthorship W4387208071A5039000174 @default.
• W4387208071 hasAuthorship W4387208071A5042095217 @default.
• W4387208071 hasConcept C121608353 @default.
• W4387208071 hasConcept C126322002 @default.
• W4387208071 hasConcept C126838900 @default.
• W4387208071 hasConcept C126894567 @default.
• W4387208071 hasConcept C141071460 @default.
• W4387208071 hasConcept C168563851 @default.
• W4387208071 hasConcept C2777416452 @default.
• W4387208071 hasConcept C2778220009 @default.
• W4387208071 hasConcept C2778357063 @default.
• W4387208071 hasConcept C29730261 @default.
• W4387208071 hasConcept C2989005 @default.
• W4387208071 hasConcept C509974204 @default.
• W4387208071 hasConcept C61943457 @default.
• W4387208071 hasConcept C71924100 @default.
• W4387208071 hasConceptScore W4387208071C121608353 @default.
• W4387208071 hasConceptScore W4387208071C126322002 @default.
• W4387208071 hasConceptScore W4387208071C126838900 @default.
• W4387208071 hasConceptScore W4387208071C126894567 @default.
• W4387208071 hasConceptScore W4387208071C141071460 @default.
• W4387208071 hasConceptScore W4387208071C168563851 @default.
• W4387208071 hasConceptScore W4387208071C2777416452 @default.
• W4387208071 hasConceptScore W4387208071C2778220009 @default.
• W4387208071 hasConceptScore W4387208071C2778357063 @default.
• W4387208071 hasConceptScore W4387208071C29730261 @default.
• W4387208071 hasConceptScore W4387208071C2989005 @default.
• W4387208071 hasConceptScore W4387208071C509974204 @default.
• W4387208071 hasConceptScore W4387208071C61943457 @default.
• W4387208071 hasConceptScore W4387208071C71924100 @default.
• W4387208071 hasIssue "2" @default.
• W4387208071 hasLocation W43872080711 @default.
• W4387208071 hasLocation W43872080712 @default.
• W4387208071 hasOpenAccess W4387208071 @default.
• W4387208071 hasPrimaryLocation W43872080711 @default.
• W4387208071 hasRelatedWork W1966946680 @default.
• W4387208071 hasRelatedWork W2384708512 @default.
• W4387208071 hasRelatedWork W2404243584 @default.
• W4387208071 hasRelatedWork W2409536117 @default.
• W4387208071 hasRelatedWork W2966036943 @default.
• W4387208071 hasRelatedWork W3029213237 @default.
• W4387208071 hasRelatedWork W3029595631 @default.
• W4387208071 hasRelatedWork W3104537559 @default.
• W4387208071 hasRelatedWork W3110899715 @default.
• W4387208071 hasRelatedWork W4206581437 @default.
• W4387208071 hasVolume "117" @default.
• W4387208071 isParatext "false" @default.
• W4387208071 isRetracted "false" @default.
• W4387208071 workType "article" @default.